Emerging studies suggest Retatrutide , a dual agonist targeting both GLP-1 and GIP , could represent a notable development for body treatment. Preliminary patient trials have demonstrated impressive losses in visceral mass , potentially outperforming current obesity therapies . Despite this, addi